ABL1 Q252H Recombinant humaan actief eiwit Kinase

The emergence of mutations in the BCR::ABL1 kinase domain (KD) impairs Imatinib Mesylate binding capacity, thus contributing to Imatinib Mesylate resistance. Identification of these mutations is important for treatment decisions and precision medicine in chronic myeloid leukaemia (CML). ABL1 Q252H Recombinant Human Active Protein Kinase is a recombinant ABL1 Q252H protein that can be used to study ABL1 Q252H-related functions[1].

12352211

Bcr-Abl

Protein Tyrosine Kinase/RTK

Cancer

[ABL1Q252HRecombinantHumanActiveProteinKinase]

[1]Yusoff YM, et al. Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance. Malays J Pathol. 2024 Dec;46 (3) :431-439.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-E70639/

Enzyme

No Development Reported